EGFR-IN-144
EGFR-IN-144 (Compound 4B) exhibits inhibitory activities against EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL) . EGFR-IN-144 exhibits cytotoxicity in multiple cancer cell with GI50 of nanomolare levels. EGFR-IN-144 downregulates the expressions of mTOR, TNF-α, and IL-6, arrests the cell cycle at G1/S phase, and induces apoptosis[1].
Product Specifications
UNSPSC
12352211
Target
Apoptosis; EGFR; Interleukin Related; Microtubule/Tubulin; TNF Receptor
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
COC1=CC=C(C=C1OC)/C=C/C(C2=C(N(N=N2)C3=C(Cl)C=C(Cl)C=C3)C)=O
Molecular Formula
C20H17Cl2N3O3
Molecular Weight
418.27
References & Citations
[1]Shaheen M A, et al. Development of 1, 2, 3-triazole hybrids as multi-faced anticancer agents co-targeting EGFR/mTOR pathway and tubulin depolymerization[J]. Bioorganic Chemistry, 2025: 108153.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CS808653 5x 5 µm
Tissue FFPE Sections, Multiple urinary system sites
Sign In for Pricing
View Details 
